Daxor Corporation Awarded $1.9M Contract by The U.S. Air Force for Development of its Next Generation Tracer System in its Point-of-Care Blood Volume Analyzer
Daxor (Nasdaq: DXR) has been awarded a $1.9 million two-year contract from the U.S. Air Force (USAF) to support the development of a next-generation point-of-care blood volume analyzer. This marks Daxor's third consecutive contract with the USAF, focusing on creating a novel fluorescent tracer and optical sensing technology for both military and civilian applications.
The funding comes through the USAF's Tactical Funding Increase (TACFI) Program of AFWERX, aimed at fostering innovation and rapid development of affordable technologies. Daxor's blood volume analysis (BVA) diagnostic is designed to improve decision-making in fluid resuscitation and blood transfusions, potentially enhancing patient survival rates and outcomes in combat casualty care and civilian settings.
Daxor (Nasdaq: DXR) ha ricevuto un contratto di 1,9 milioni di dollari della durata di due anni dalla U.S. Air Force (USAF) per supportare lo sviluppo di un analizzatore di volume sanguigno portatile di nuova generazione. Questo segna il terzo contratto consecutivo di Daxor con l'USAF, concentrandosi sulla creazione di un innovativo tracciante fluorescente e tecnologia di rilevamento ottico per applicazioni sia militari che civili.
I fondi provengono dal Programma di Aumento dei Fondi Tattici (TACFI) dell'AFWERX, volto a promuovere l'innovazione e lo sviluppo rapido di tecnologie accessibili. L'analisi del volume sanguigno (BVA) di Daxor è progettata per migliorare il processo decisionale nella rianimazione con fluidi e nelle trasfusioni di sangue, potenzialmente aumentando i tassi di sopravvivenza dei pazienti e i risultati nelle cure in caso di combattimento e in contesti civili.
Daxor (Nasdaq: DXR) ha sido otorgado un contrato de dos años por un valor de 1.9 millones de dólares por parte de la Fuerza Aérea de los EE. UU. (USAF) para apoyar el desarrollo de un analizador de volumen sanguíneo de atención médica de próxima generación. Este es el tercer contrato consecutivo de Daxor con la USAF, que se centra en crear un nuevo trazador fluorescente y tecnología de detección óptica para aplicaciones militares y civiles.
El financiamiento proviene del Programa de Aumento de Fondos Tácticos (TACFI) de AFWERX, que tiene como objetivo fomentar la innovación y el desarrollo rápido de tecnologías asequibles. El análisis del volumen sanguíneo (BVA) de Daxor está diseñado para mejorar la toma de decisiones en la reanimación con fluidos y transfusiones de sangre, lo que podría aumentar las tasas de supervivencia de los pacientes y los resultados en el cuidado de bajas de combate y en entornos civiles.
Daxor (Nasdaq: DXR)는 미국 공군(USAF)으로부터 2년 동안 190만 달러 규모의 계약을 체결하여 차세대 포인트 오브 케어 혈액량 분석기 개발을 지원합니다. 이는 Daxor의 세 번째 연속 계약이며, 군과 민간 응용을 위한 혁신적인 형광 추적기 및 광학 감지 기술 창출에 초점을 맞추고 있습니다.
자금은 혁신 및 경제적인 기술의 빠른 개발을 촉진하기 위한 AFWERX의 전술 자금 증대 프로그램(TACFI)을 통해 제공됩니다. Daxor의 혈액량 분석(BVA) 진단은 체액 재수화 및 혈액 수혈 시 의사결정을 개선하도록 설계되어 있으며, 전투 부상 치료 및 민간 환경에서 환자의 생존율과 결과를 향상시킬 수 있습니다.
Daxor (Nasdaq: DXR) a reçu un contrat de 1,9 million de dollars d'une durée de deux ans de l'U.S. Air Force (USAF) pour soutenir le développement d'un analyseur de volume sanguin de nouvelle génération pour soins sur le terrain. Cela marque le troisième contrat consécutif de Daxor avec l'USAF, axé sur la création d'un nouveau traceur fluorescent et d'une technologie de détection optique pour des applications militaires et civiles.
Le financement provient du Programme d'augmentation des fonds tactiques (TACFI) d'AFWERX, visant à favoriser l'innovation et le développement rapide de technologies abordables. Le diagnostic d'analyse du volume sanguin (BVA) de Daxor est conçu pour améliorer la prise de décision dans la réanimation liquidienne et les transfusions sanguines, potentiellement augmentant les taux de survie et les résultats des patients dans les soins aux blessés en combat ainsi que dans les contextes civils.
Daxor (Nasdaq: DXR) hat einen 2-Jahres-Vertrag über 1,9 Millionen US-Dollar von der U.S. Air Force (USAF) erhalten, um die Entwicklung eines Blutvolumenanalysators der nächsten Generation für die Patientenversorgung zu unterstützen. Dies markiert den dritten aufeinanderfolgenden Vertrag von Daxor mit der USAF, der sich darauf konzentriert, einen neuen fluoreszierenden Tracer und optische Sensortechnologie für militärische und zivile Anwendungen zu entwickeln.
Die Finanzierung erfolgt über das Programm zur Erhöhung der taktischen Mittel (TACFI) von AFWERX, das darauf abzielt, Innovationen und die schnelle Entwicklung erschwinglicher Technologien zu fördern. Die Blutvolumenanalyse (BVA) von Daxor ist darauf ausgelegt, die Entscheidungsfindung bei der Flüssigkeitsreihe und Bluttransfusionen zu verbessern, was potenziell die Überlebensraten der Patienten und die Ergebnisse in der Behandlung von Kampfverletzten und in zivilen Umgebungen verbessern kann.
- Awarded $1.9 million contract from U.S. Air Force
- Third consecutive contract with USAF, indicating ongoing successful collaboration
- Development of next-generation point-of-care blood volume analyzer
- Potential for improved patient outcomes in military and civilian applications
- None.
The
The contract's focus on developing next-generation blood volume analyzer technology could potentially expand Daxor's market reach in both military and civilian sectors. This dual-use potential is particularly valuable, as it may lead to increased revenue streams and market diversification.
Investors should note that while this contract provides immediate revenue, its real value lies in the potential for future commercialization of the developed technology. The competitive nature of the TACFI Program also lends credibility to Daxor's technological capabilities, which could attract further investment and partnerships.
Daxor's development of a novel fluorescent tracer and optical sensing technology for blood volume measurement represents a significant advancement in point-of-care diagnostics. This technology has the potential to revolutionize fluid resuscitation and blood transfusion practices in both military and civilian healthcare settings.
The ability to make more informed decisions about fluid management can lead to improved patient survival rates and outcomes, addressing a critical need in emergency and critical care medicine. This innovation could position Daxor as a leader in precision medicine for fluid management, potentially expanding its market share in the medical device industry.
The continued support from the USAF suggests strong confidence in the technology's potential impact, which could accelerate its adoption in military healthcare systems and subsequently in civilian hospitals.
Daxor's success in securing this contract through the highly competitive AFWERX TACFI Program highlights the company's strong innovation capabilities and market potential. This achievement could significantly enhance Daxor's reputation in the medical technology sector, potentially attracting more investors and partners.
The dual-use nature of the technology being developed - suitable for both military and civilian applications - opens up multiple market opportunities. This versatility could lead to a wider adoption of Daxor's blood volume analysis technology across various healthcare settings.
Investors should monitor how this development impacts Daxor's market position relative to competitors in the point-of-care diagnostics space. The company's ability to leverage this contract into commercial success and market expansion will be important for long-term growth and shareholder value.
Oak Ridge, TN, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it has been awarded a
Michael Feldschuh, Daxor’s President and CEO, highlighted the significance of this latest agreement: “We're proud to continue our collaboration with the USAF, marking our third consecutive contract. Our ongoing alliance accelerates the development of our innovative technology, making precise blood volume measurement faster and more accessible in both combat casualty care and civilian use. Our blood volume analysis (BVA) diagnostic is revolutionizing current practices allowing medical teams to make more informed choices about fluid resuscitation and blood transfusions, improving patient survival rates and overall outcomes."
The funding was made possible through the highly competitive USAF’s Tactical Funding Increase (TACFI) Program of AFWERX, the USAF team of innovators who encourage and facilitate connections across industry, academia, and the military to create transformative opportunities for the development of rapid and affordable commercial and military technologies and solutions that meet critical healthcare needs.
About Daxor Corporation
Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100® (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com. Sign up to receive news on Daxor’s innovative technology HERE.
Forward-Looking Statements
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR
1-516-222-2560
brets@coreir.com
FAQ
What is the value and duration of the contract Daxor (DXR) received from the U.S. Air Force?
What technology is Daxor (DXR) developing with the USAF contract?
How many consecutive contracts has Daxor (DXR) received from the U.S. Air Force?
What program provided the funding for Daxor 's (DXR) contract with the USAF?
